Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Investor Daily.
Press releases published on August 11, 2025
Hallador Energy Company Reports Second Quarter 2025 Financial and Operating Results
- Q2 Total Revenue up 10% YoY to $102.9 Million - - Q2 Net Income Increases to $8.2 Million or $0.19 Earnings per Share – - Q2 Operating Cash Flow of $11.4 Million - - Q2 Adjusted EBITDA increases to $3.4 Million - TERRE HAUTE, Ind., Aug. 11, 2025 (GLOBE …
BioVie Inc. Announces Closing of $12 Million Public Offering
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and …
Quest Resource Holding Corporation Reports Second Quarter 2025 Financial Results
Generated $3.9 million in operating cash flow in the second quarter and reduced debt by $6.6 million year to date Posted sequential improvements in gross profits and adjusted EBITDA Roll out of Operational Excellence Initiatives is on track and continuing …
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 …
TELA Bio Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended …
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including pancreatic cancer and GBM pilot …
HighPeak Energy, Inc. Announces Second Quarter 2025 Financial and Operating Results
FORT WORTH, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales volumes …
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million Transaction …
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase …
Fluence Energy, Inc. Reports Third Quarter 2025 Results; Reaffirms Fiscal Year 2025 Guidance
ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its …
Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results
Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of $ …
MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended June 30, 2025
Results for the Quarter Ended June 30, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.39, compared to $0.37 for the quarter ended March 31, 2025 Net asset value per share as of the end of the quarter was $14.75, …
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib OPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on …
Gevo Reports Second Quarter 2025 Financial Results
Achieves Positive Net Income in the Second Quarter and Positive Adjusted EBITDA1 for the Second Quarter and Six Months Ended June 30, 2025 Positive Net Income Attributable to Gevo of $2.1 million in the Second Quarter Positive Adjusted EBITDA1 of $17 …
Xenon Reports Second Quarter 2025 Financial Results & Business Update
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated – Phase 1 healthy volunteer …
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying transitions to …
Harrow Announces Second-Quarter 2025 Financial Results
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 …
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment …
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference »
Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …